|
1
|
El-Serag HB and Mason AC: Rising incidence
of hepatocellular carcinoma in the United States. N Engl J Med.
340:745–750. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sangiovanni A, Del Ninno E, Fasani P, De
Fazio C, Ronchi G, Romeo R, Morabito A, De Franchis R and Colombo
M: Increased survival of cirrhotic patients with a hepatocellular
carcinoma detected during surveillance. Gastroenterology.
126:1005–1014. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Merchant N, David CS and Cunningham SC:
Early hepatocellular carcinoma: Transplantation versus resection:
The case for liver resection. Int J Hepatol. 2011:1420852011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Burrel M, Reig M, Forner A, Barrufet M, de
Lope CR, Tremosini S, Ayuso C, Llovet JM, Real MI and Bruix J:
Survival of patients with hepatocellular carcinoma treated by
transarterial chemoembolisation (TACE) using drug eluting beads.
Implications for clinical practice and trial design. J Hepatol.
56:1330–1335. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Settles B, Stevenson A, Wilson K, Mack C,
Ezell T, Davis MF and Taylor LD: Down-regulation of cell adhesion
molecules LFA-1 and ICAM-1 after in vitro treatment with the
anti-TNF-alpha agent thalidomide. Cell Mol Biol (Noisy-le-grand).
47:1105–1114. 2001.PubMed/NCBI
|
|
6
|
Sun P, Zhang LM, Sun DJ and Dong LL:
Inhibitory effect of thalidomide on growth of human hepatoma cell
line SMMC 7721 cells. Zhonghua Zhong Liu Za Zhi. 31:582–586.
2009.(In Chinese). PubMed/NCBI
|
|
7
|
Tan H, Chen H, Xu C, Ge Z, Gao Y, Fang J,
Liu W and Xiao S: Role of vascular endothelial growth factor in
angiodysplasia: An interventional study with thalidomide. J
Gastroenterol Hepatol. 27:1094–1101. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Galustian C, Meyer B, Labarthe MC, Dredge
K, Klaschka D, Henry J, Todryk S, Chen R, Muller G, Stirling D, et
al: The anti-cancer agents lenalidomide and pomalidomide inhibit
the proliferation and function of T regulatory cells. Cancer
Immunol Immunother. 58:1033–1045. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Agliano A, Martin-Padura I, Marighetti P,
Gregato G, Calleri A, Prior C, Redrado M, Calvo A and Bertolini F:
Therapeutic effect of lenalidomide in a novel xenograft mouse model
of human blastic NK cell lymphoma/blastic plasmacytoid dendritic
cell neoplasm. Clin Cancer Res. 17:6163–6173. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Park E, Levis WR, Greig N, Jung E and
Schuller-Levis G: Effect of thalidomide on nitric oxide production
in lipopolysaccharide-activated RAW 264.7 cells. J Drugs Dermatol.
9:330–333. 2010.PubMed/NCBI
|
|
11
|
Dmoszynska A, Podhorecka M, Klimek P and
Grzasko N: Lovastatin and thalidomide have a combined effect on the
rate of multiple myeloma cell apoptosis in short term cell
cultures. Eur J Clin Pharmacol. 62:325–329. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dmoszynska A, Podhorecka M, Manko J,
Bojarska-Junak A, Rolinski J and Skomra D: The influence of
thalidomide therapy on cytokine secretion, immunophenotype, BCL-2
expression and microvessel density in patients with resistant or
relapsed multiple myeloma. Neoplasma. 52:175–181. 2005.PubMed/NCBI
|
|
13
|
Vaithilingam V, Oberholzer J, Guillemin GJ
and Tuch BE: Beneficial effects of desferrioxamine on encapsulated
human islets-in vitro and in vivo study. Am J Transplant.
10:1961–1969. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
van de Donk NW, Wittebol S, Minnema MC and
Lokhorst HM: Lenalidomide (Revlimid) combined with continuous oral
cyclophosphamide (endoxan) and prednisone (REP) is effective in
lenalidomide/dexamethasone-refractory myeloma. Br J Haematol.
148:335–337. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rao KV: Lenalidomide in the treatment of
multiple myeloma. Am J Health Syst Pharm. 64:1799–1807. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ezell TN, Maloney N, Githua JW and Taylor
LD: Exposure to the anti-TNF-alpha drug thalidomide induces
apoptotic cell death in human T leukemic cells. Cell Mol Biol
(Noisy-le-grand). 49:1117–1124. 2003.PubMed/NCBI
|
|
17
|
Mitsiades N, Mitsiades CS, Poulaki V,
Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP and
Anderson KC: Apoptotic signaling induced by immunomodulatory
thalidomide analogs in human multiple myeloma cells: Therapeutic
implications. Blood. 99:4525–4530. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Folkman J: Tumor angiogenesis: Therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
